Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23091732 | 0.88 | ABL1 (0.43) | ABL1LMNAPOLB | |
| SCHEMBL23091810 | 0.86 | ABL1 (0.51) | ABL1 | |
| SCHEMBL23091727 | 0.84 | ABL1 (0.47) | ABL1 | |
| SCHEMBL23091808 | 0.83 | ABL1 (0.50) | ABL1TRPV1 | |
| SCHEMBL29687246 | 0.83 | ABL1 (0.47) | ABL1TRPV1 | |
| SCHEMBL23091646 | 0.83 | ABL1 (0.47) | ABL1TRPV1 | |
| SCHEMBL23091775 | 0.82 | ABL1 (0.47) | ABL1 | |
| SCHEMBL23091743 | 0.82 | ABL1 (0.52) | ABL1 | |
| SCHEMBL23091741 | 0.80 | TRPV1 (0.53) | ABL1TRPV1 | |
| SCHEMBL23091728 | 0.80 | ABL1 (0.45) | ABL1TRPV1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028387-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-07-20 | — | — | EP | claimed |
| CN-114502544-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2021048567-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2021-03-18 | — | — | WO | claimed |
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4028387-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| CN-114502544-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021048567-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | ABL1 2/4885TRPV1 1085/4885LMNA 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.